# US 2012/0252765 A1 · Use of irbesartan for the preparation of a medicament for the prevention of hospitalization for heart failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252765 A1
- Document ID: US20120252765A1
- Status: Published application
- Kind: A1
- Application number: 13/405,896
- Filed: 2012-02-27
- Published: 2012-10-04
- Earliest claimed: 2009-08-31
- Assignees: Sanofi
- Inventors: Catherine MARCHESE; Christophe GAUDIN
- Web page: https://patentgrep.com/patent/US20120252765A1

## CPC

- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/12: Antihypertensives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Use of irbesartan or one of its pharmaceutically acceptable salts for the preparation of a medicament for the prevention of hospitalization for heart failure.

## Claims

### Claim 1

A method of preventing hospitalization for heart failure in a patient, comprising administering to said patient an effective dose of irbesartan or a pharmaceutically acceptable salt thereof, wherein said patient has a history of atrial fibrillation or a current atrial fibrillation.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the patient has at least the three following factors:
an evidence of atrial fibrillation,
an evidence of high risk of vascular events, and
a systolic blood pressure of at least 110 mm Hg.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the patient has a left ventricular dysfunction with left ventricular ejection fraction estimated by echocardiogram or angiogram (radionuclide or contrast) to be <45%.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the patient further has at least one of the following risk factors:
a) age 75 years or greater;
b) on treatment for systemic hypertension;
c) prior stroke, transcient ischemic attack or non-central nervous system systemic embolus;
d) left ventricular dysfunction with left ventricular ejection fraction estimated by echocardiogram or angiogram (radionuclide or contrast) to be <45%;
e) peripheral vascular disease (previous peripheral artery revascularization, limb and foot amputation, or the combination of current intermittent claudication and ankle arm systolic blood pressure ratio<0.9); or
f) age 55 to 74 years and either:
f1) diabetes mellitus requiring drug therapy, or
f2) documented previous myocardial infarction or documented coronary artery disease.

### Claim 5 (depends on 1)

The method according to claim 1 wherein irbesartan is irbesartan form A.

### Claim 6 (depends on 1)

The method according to claim 1 wherein irbesartan is administered at a dose up to 300 mg/day.

### Claim 7 (depends on 5)

The method according to claim 5 wherein irbesartan is administered at a dose up to 300 mg/day.

### Claim 8 (depends on 1)

The method according to claim 1 wherein the patient is also treated with at least one of the following medication:
a) clopidogrel and acetylsalicylic acid,
b) oral anticoagulant,
c) acetylsalicylic acid.

### Claim 9 (depends on 5)

The method according to claim 5 wherein the patient is also treated with at least one of the following medication:
d) clopidogrel and acetylsalicylic acid,
e) oral anticoagulant,
f) acetylsalicylic acid.

### Claim 10 (depends on 7)

The method according to claim 7 wherein the patient is also treated with at least one of the following medication:
g) clopidogrel and acetylsalicylic acid,
h) oral anticoagulant,
i) acetylsalicylic acid.

### Claim 11 (depends on 1)

The method according to claim 1 wherein the prevention of hospitalization for heart failure is a decrease of 14% in the risk of heart failure hospitalization.

### Claim 12 (depends on 5)

The method according to claim 5 wherein the prevention of hospitalization for heart failure is a decrease of 14% in the risk of heart failure hospitalization.

### Claim 13 (depends on 7)

The method according to claim 7 wherein the prevention of hospitalization for heart failure is a decrease of 14% in the risk of heart failure hospitalization.

### Claim 14 (depends on 10)

The method according to claim 10 wherein the prevention of hospitalization for heart failure is a decrease of 14% in the risk of heart failure hospitalization.

### Claim 15 (depends on 1)

The method according to claim 1 wherein the prevention of hospitalization for heart failure is a decrease of 8.7% in the number of days of hospitalization for cardiovascular reasons.

### Claim 16 (depends on 5)

The method according to claim 5 wherein the prevention of hospitalization for heart failure is a decrease of 8.7% in the number of days of hospitalization for cardiovascular reasons.

### Claim 17 (depends on 7)

The method according to claim 7 wherein the prevention of hospitalization for heart failure is a decrease of 8.7% in the number of days of hospitalization for cardiovascular reasons.

### Claim 18 (depends on 10)

The method according to claim 10 wherein the prevention of hospitalization for heart failure is a decrease of 8.7% in the number of days of hospitalization for cardiovascular reasons.

### Claim 19 (depends on 14)

The method according to claim 14 wherein the prevention of hospitalization for heart failure is a decrease of 8.7% in the number of days of hospitalization for cardiovascular reasons.
